Heart failure has been reported as a rare side effect of bevacizumab, a chemotherapeutic agent, used in the treatment of breast cancer. However, reversible left ventricular systolic dysfunction with a pattern similar to stress-induced cardiomyopathy has not been reported. The etiopathogenesis of stress-induced cardiomyopathy is poorly understood. Given this uncertainty, we should always look out for other potential offenders causing similar presentation, rather than label all of them as "stress-induced".
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3758098 | PMC |
| http://dx.doi.org/10.1016/j.jcdr.2013.02.017 | DOI Listing |
Publication Analysis
Top Keywords
stress-induced cardiomyopathy
8
reversible myocardial
4
myocardial dysfunction
4
dysfunction intraocular
4
intraocular bevacizumab
4
bevacizumab administration
4
administration heart
4
heart failure
4
failure reported
4
reported rare
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!